Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-8000 in Japanese Patients With Non-Hodgkin's Lymphoma
NCT02697552Phase 1Completed
- Sponsor
- HUYABIO International, LLC
- Start
- Mar 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tucidinostat in non-Hodgkin lymphoma (NHL), sponsored by HUYABIO International, LLC. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2014; status: completed.
02
Drugs
tucidinostat
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02697552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697552.